PR90436

SHENZHEN, China, July 2, 2021 /PRNewswire=KYODO JBN/ --

On April 30th, SonoScape received the CE-marking, the product's "Passport to

Europe", for its linear-array echoendoscope EG-UC5T. This further expands

SonoScape's endoscopic ultrasound (EUS) portfolio in the international market.

Reaping the benefits of decades of ultrasound technology know-how, SonoScape's

EUS product line officially debuted in September 2019, when its 360°

radial-array echoendoscope EG-UR5 obtained the CE Marking, leaping to the 4th

company in the world to master the core technology of EUS.

EG-UC5T is characterised by its large, 4.0-mm instrument channel and its short

rigid distal end, pushing the boundaries of therapeutic excellence. With the

arrival of the linear-array echoendoscope EG-UC5T, SonoScape users are not only

able to perform the adequate tissue sampling, but also various therapeutic

interventional endoscopic procedures under the sonographic guidance. This is a

true "best of the two worlds", a golden key to reveal what's behind the GI

tract mucosa and to unlock the growing possibilities of advanced endoscopy.

"SonoScape's EUS portfolio will certainly extend the company's path into more

and larger hospitals. This again underpins the company's leading role in the

global digestive endoscopy market." said Steven He, Sales Director of Endoscopy

Division at SonoScape: "We have achieved great results with our current

gastrointestinal endoscopes, and I am confident that the new linear-array

echoendoscopes will set us to a higher success."

The last 25 years have witnessed a major expansion of EUS to various

applications, both diagnostic and therapeutic, as noted in Friedberg SR,

Lachter J, World Journal of Gastrointestinal Endoscopy (2017).  Focused on

delivering high quality products, SonoScape continues to bring significant

value to the world of endoscopy.

About SonoScape

Founded in 2002 in Shenzhen, China, SonoScape has committed itself to "Caring

for life through innovation" by providing ultrasound and endoscopy solutions

and delivering first-rate services. It now has seven R&D centers in Shenzhen,

Shanghai, Harbin, Wuhan, Tokyo, Silicon Valley and Seattle. SonoScape invests

nearly 20% of its revenues into R&D in recent 3 years, with more advanced

products to be introduced into the pipeline.

SOURCE:  SonoScape Medical Corporation

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=395273

   Caption: CE Marking